SORL1 Protein

📖 Wiki Page

protein2914 wordssynced 2026-04-02

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">SORL1 Protein</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">[app](/genes/app)</td>
<td>Amyloid production</td>
</tr>
<tr>
<td class="label">[psen1](/proteins/psen1-protein)/[psen2](/proteins/psen2-protein)</td>
<td>[gamma-secretase](/proteins/gamma-secretase)</td>
</tr>
<tr>
<td class="label">[apoe](/proteins/apoe-protein)</td>
<td>Lipid transport</td>
</tr>
<tr>
<td class="label">[BACE1</td>
<td>[Beta-secretase](/entities/bace1)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">187 edges</a></td>
</tr>
</table>

Pathway Diagram

...

Pathway Diagram

Mermaid diagram (expand to render)

Introduction

Sorl1 (Sortilin Related Receptor 1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

SORL1 (Sortilin-Related Receptor 1), also known as SORLA (Sorting protein-related receptor with A-type repeats) or LR11, encodes a large type-1 transmembrane receptor that functions as an endocytic sorting receptor critical for intracellular trafficking [@bhalla2023] of [amyloid precursor protein[/[3[/[3[/[3[/[3](/proteins/gsk3-beta) ([app](/genes/app) and [amyloid-beta](/proteins/amyloid-beta) ([amyloid-beta](/proteins/amyloid-beta). SORL1 is now recognized as one of the most important genetic risk factors for [Alzheimer [@willnow2013]'s disease], with increasing evidence supporting its status as the fourth causal AD gene after [app](/genes/app), [psen1](/proteins/psen1-protein), and [psen2](/proteins/psen2-protein) [Rogaeva et al., 2007](https://doi.org/10.1038/ng1943). Loss-of-function variants in SORL1 lead to endosomal dysfunction, increased amyloidogenic processing of [app](/genes/app), and elevated [amyloid-beta](/proteins/amyloid-beta) production — directly linking endosomal trafficking defects to Alzheimer's pathogenesis ([Andersen et al., 2005](https://doi.org/10.1073/pnas.0503689102)). [@scherzer2004]

Gene and Protein Structure

Gene

SORL1 is located on chromosome 11q23.2-q24.2 and spans approximately 180 kb with 48 exons. The gene encodes a 2214-amino acid protein with a molecular weight of approximately 250 kDa. Expression is highest in the brain, particularly in [neurons](/entities/neurons) of the [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and cerebellum [Scherzer et al., 2004](https://doi.org/10.1001/archneur.61.8.1200) ([Knupp et al., 2022](https://doi.org/10.1007). [@knupp2022]

Protein Domains

The SORLA protein is a multidomain receptor belonging to both the vacuolar protein sorting 10 protein (VPS10P) domain receptor family and the low-density lipoprotein receptor (LDLR) family. Its extracellular region contains the following domains [Willnow & Andersen, 2013](https://doi.org/10.1016/j.nbd.2013.07.011) ([Willnow TE et al., 2013](https://doi.org/10.1016/j.nbd.2013.07.011)): [@willnow2013]

VPS10P domain: An N-terminal domain (~700 amino acids) that binds [amyloid-beta](/proteins/amyloid-beta) and directs it toward lysosomal degradation. X-ray crystallography has mapped the [amyloid-beta](/proteins/amyloid-beta) binding site to this domain, and disruption reduces lysosomal catabolism of [amyloid-beta](/proteins/amyloid-beta).

YWTD β-propeller with EGF domain: A six-bladed β-propeller domain flanked by an EGF-like domain, characteristic of LDLR family members. This domain mediates pH-dependent ligand release in endosomes.

Complement-type repeat (CR) domains: Eleven CR domains (also called LDLR class A repeats) that interact in a 1:1 stoichiometric complex with [app](/genes/app), mediating the direct binding that controls [app](/genes/app) trafficking.

Fibronectin type-III (3Fn) domains: Six 3Fn domains involved in protein-protein interactions and SORLA dimerization. Together with VPS10P domains, 3Fn domains mediate homodimerization within retromer-positive endosomal tubules ([Bhalla et al., 2023](https://doi.org/10.1073/pnas.2212180120)).

Single transmembrane domain: Anchors the receptor in the membrane.

Cytoplasmic tail: A short intracellular domain containing sorting motifs that interact with adaptor proteins (GGA, PACS1) and the retromer complex to direct endosomal trafficking ([Holstege et al., 2024](https://doi.org/10.1007).

Function in APP Trafficking

Normal SORL1 Function

SORL1 plays a central role in determining the intracellular fate of [app](/genes/app) within the endosomal system [Andersen et al., 2005](https://doi.org/10.1073/pnas.0503689102): [@bhalla2023]

[app](/genes/app) binding: SORLA binds newly synthesized [app](/genes/app) in the trans-Golgi network (TGN) through its CR domains, retaining [app](/genes/app) in recycling pathways and preventing its entry into [amyloid-beta](/proteins/amyloid-beta)-generating compartments.

Retromer-mediated retrograde transport: Acting together with the retromer trafficking complex (VPS26-VPS29-VPS35), SORLA directs [app](/genes/app) from early endosomes back to the TGN, reducing the time [app-protein](/entities/app-protein) spends in endosomes where [BACE1[/entities/bace1/[Bhalla[/entities/bace1/[Bhalla[/entities/bace1/](/entities/bhalla) et al., 2023)https://doi.org/10.1073/pnas.2212180120) ([Bhalla et al., 2024](https://doi.org/10.1073/pnas.2408262121)).

Consequences of SORL1 Deficiency

When SORL1 is underexpressed or carries loss-of-function variants: [@bhalla2024]

[APP](/entities/app-protein) is shunted from recycling pathways into [amyloid-beta](/proteins/amyloid-beta)-generating compartments
Increased exposure of APP to [BACE1 leads to elevated [amyloid-beta](/proteins/amyloid-beta) production
Endosomes become enlarged (endosomal swelling), a hallmark early pathological feature of [alzheimers](/diseases/alzheimers-disease)
Reduced [Aβ[/entities/[Amyloid-Beta[/entities/[Amyloid-Beta[/entities/[Amyloid-Beta[/entities//entities/[Amyloid-Beta](/entities/Amyloid-Beta) clearance through impaired lysosomal targeting
Disrupted axonal transport homeostasis and altered neuronal excitability [Bhalla et al., 2025](https://doi.org/10.1101/2025.07.28.667160v1)

Genetic Association with Alzheimer's Disease

GWAS and Common Variants

The landmark study by Rogaeva et al. (2007) first identified SORL1 as an AD risk gene through family-based association analysis across multiple ethnic cohorts. Two clusters of intronic SNPs were associated with late-onset AD and may regulate tissue-specific SORL1 expression [Rogaeva et al., 2007](https://doi.org/10.1038/ng1943). Subsequent genome-wide association studies (GWAS) have consistently replicated the SORL1 association, establishing it alongside other AD susceptibility loci including [apoe](/proteins/apoe-protein). [@bhalla2025]

p.Tyr1816Cys (Y1816C): Identified in three unrelated families with AD. This variant impairs the physiologically relevant dimerization needed for SORLA to engage in retromer-dependent endosomal recycling of neuronal cargo, causing autosomal dominant AD [Bhalla et al., 2024](https://doi.org/10.1073/pnas.2408262121).
p.Cys1431fs (C1431fs): A rare protein-truncating deletion found in siblings with early-onset AD. Heterozygous carriers show increased APP accumulation in early endosomes (p=0.002), endosomal swelling (p=0.004), and elevated Aβ42/Aβ40 secretion [PMC, 2024](https://pmc.ncbi.nlm.nih.gov/articles/PMC11710782/).

SORL1 as the Fourth Causal AD Gene

The convergence of genetic and functional evidence has led to SORL1 being increasingly recognized as a causal AD gene, not merely a risk modifier: [@bhalla2025a]

Multiple rare variants segregate with AD in families (autosomal dominant pattern)
Loss-of-function variants cause amyloid accumulation through a well-defined molecular mechanism
Complete loss of SORL1 in mouse models increases brain [amyloid-beta](/proteins/amyloid-beta) levels
The effect size of SORL1 PTVs approaches that of [psen1](/proteins/psen1-protein)/[psen2](/proteins/psen2-protein) mutations

Role in Endosomal Pathway Dysfunction

The Endosomal Hypothesis of AD

SORL1 is a key gene supporting the endosomal hypothesis of Alzheimer's Disease, which posits that endosomal trafficking dysfunction is an early and causative event in AD pathogenesis, particularly in late-onset AD and [Down syndrome-associated AD]: [@amyloidbeta]

Endosomal enlargement is one of the earliest pathological changes in AD brain, preceding amyloid plaque deposition
Multiple AD risk genes (SORL1, BIN1, PICALM, CD2AP, RIN3) converge on endosomal trafficking pathways
[apoe4](/diseases/apoe4) also impairs endosomal function through altered lipid trafficking
Endosomal dysfunction increases both Aβ production and tau] pathology

Interaction with Retromer Complex

SORLA functions in concert with the retromer complex (VPS26-VPS29-VPS35), which mediates retrograde transport of cargo from endosomes to the TGN. SORLA dimerization via both its 3Fn and VPS10P domains occurs specifically within retromer-positive endosomal tubules [Bhalla et al., 2023](https://doi.org/10.1073/pnas.2212180120). Disruption of this interaction (as with the Y1816C variant) impairs APP recycling and promotes amyloidogenic processing. VPS35 mutations have also been linked to [parkinsons](/diseases/parkinsons-disease), suggesting retromer dysfunction as a shared mechanism across neurodegenerative conditions. [@sorl]

SORL1 Expression in the Brain

SORL1 is predominantly expressed in [neurons](/entities/neurons) but is also present in [microglia. In the AD brain, SORL1 expression is significantly reduced, particularly in vulnerable regions such as the [hippocampus](/brain-regions/hippocampus) and [entorhinal [cortex](/brain-regions/cortex) [Scherzer et al., 2004)(https://doi.org/10.1001/archneur.61.8.1200). [@uniprot]

Neuronal Functions

APP sorting and [Aβ](/proteins/amyloid-beta-protein) clearance (as detailed above)
Regulation of [axonal transport](/mechanisms/axonal-transport) homeostasis
Modulation of neuronal excitability — SORL1 loss leads to altered synaptic activity, expanding its functional relevance beyond endosomal APP processing [Bhalla et al., 2025](https://doi.org/10.1101/2025.07.28.667194v1)

Microglial Functions

Ongoing studies are examining SORL1's role in [microglia](/cell-types/microglia) could enhance SORL1-retromer function and reduce endosomal dysfunction.

Endosomal pH modulators: Drugs that normalize endosomal pH could reduce [bace1](/proteins/bace1-protein) activity and improve SORL1-mediated APP sorting.

Gene therapy: Delivering functional SORL1 via [gene-therapy](/therapeutics/gene-therapy) vectors could rescue endosomal function in carriers of loss-of-function variants.

Precision medicine: Genetic screening for SORL1 variants could identify high-risk individuals for early intervention with [anti-amyloid-therapeutics](/mechanisms/anti-amyloid-therapeutics) like [lecanemab](/therapeutics/lecanemab) or [donanemab](/therapeutics/donanemab).

Biomarker Potential

SORL1 has potential as a biomarker: [@genecards]

Soluble SORL1 (sSORLA) can be measured in cerebrospinal fluid and plasma
CSF sSORLA levels correlate with AD pathology
SORL1 genotyping could be incorporated into polygenic risk scores for AD prediction alongside [plasma-biomarkers](/diagnostics/plasma-biomarkers)

Relationship to Other AD Genes

Heterozygous SORL1 loss-of-function is sufficient to cause endosomal swelling, increased APP in early endosomes, and elevated [Aβ](/proteins/amyloid-beta) secretion
iPSC [neurons](/entities/neurons) with the Y1816C variant show impaired APP sorting, disrupted [axonal transport](/mechanisms/axonal-transport), and altered neuronal activity in brain organoids
CRISPR-corrected isogenic lines confirm that SORL1 variants are causative, not merely associated
These models enable preclinical drug testing on patient-derived cells

Current Research Directions

Large-scale sequencing studies to catalog all pathogenic SORL1 variants and establish genotype-phenotype correlations
Development of SORL1 expression-enhancing therapies
Investigation of SORL1 function in non-neuronal brain cells ([microglia/Rogaeva E, et al. (2007). The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer's Disease. Nature Genetics, 39(2), 168-177. [DOI](https://doi.org/10.1038/ng1943)

2. 1. [/proteins/amyloid — Peptide whose production is modulated by SORL1

[DOI](https://doi.org/10.1073/pnas.0503689102)

[Willnow TE & Andersen OM. (2013). Sorting receptor SORLA — a trafficking path to avoid Alzheimer's Disease. Neurobiology of Disease, 55, 7-12. [DOI](https://doi.org/10.1016/j.nbd.2013.07.011)

[Scherzer CE, et al. (2004). SORL1 is genetically associated with late-onset Alzheimer's Disease in Japanese, Koreans and Caucasians. Archives of Neurology, 61(8), 1200-1207. [DOI](https://doi.org/10.1001/archneur.61.8.1200)

[Holstege H, et al. (2024). A familial missense variant in the Alzheimer's Disease gene SORL1 impairs its maturation and endosomal sorting. Acta Neuropathologica, 146, 173-195. . [DOI](https://doi.org/10.1007/s00401-023-02670-1)

[Bhalla A, et al. (2024). The SORL1 p.Y1816C variant causes impaired endosomal dimerization and autosomal dominant Alzheimer's Disease. PNAS, 121(49), e2408262121. [DOI](https://doi.org/10.1073/pnas.2408262121)

[Bhalla A, et al. (2023). Dimerization of the Alzheimer's Disease pathogenic receptor SORLA regulates its association with retromer. PNAS, 120(28), e2212180120. [DOI](https://doi.org/10.1073/pnas.2212180120)

[Bhalla A, et al. (2025). The Alzheimer's-associated SORL1 p.Y1816C variant impairs APP sorting, axonal trafficking, and neuronal activity in iPSC-derived brain models. bioRxiv. [DOI](https://doi.org/10.1101/2025.07.28.667160v1)

[Bhalla A, et al. (2025). The Alzheimer's Disease risk gene SORL1 is a regulator of excitatory neuronal function. bioRxiv. [DOI](https://doi.org/10.1101/2025.07.28.667194v1)

[PMC, 2024 - Investigating the role of SORL1 in mediating AD-specific endolysosomal phenotypes in neurons and microglia](https://pmc.ncbi.nlm.nih.gov/articles/PMC11710782/)

[Knupp A, et al. (2022). The Alzheimer's gene SORL1 is a regulator of endosomal traffic and recycling in human [neurons](/entities/neurons). Cellular and Molecular Life Sciences, 79, 162. . [DOI](https://doi.org/10.1007/s00018-022-04182-9)

[Verheijen J, et al. (2016). Risk factor SORL1: from genetic association to functional validation in Alzheimer's Disease. Acta Neuropathologica, 132, 653-665. . [DOI](https://doi.org/10.1007/s00401-016-1615-4)

Background

The study of Sorl1 (Sortilin Related Receptor 1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@omima]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@alsa]

Brain Atlas Resources

Allen Human Brain Atlas: [SORL1 expression search](https://human.brain-map.org/microarray/search/show?search_term=SORL1)
Allen Mouse Brain Atlas: [SORL1 search](https://mouse.brain-map.org/search/index.html?query=SORL1)
Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
BrainSpan Developmental Transcriptome: [SORL1 developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=SORL1)

External Links

[NCBI Gene: SORL1](https://www.ncbi.nlm.nih.gov/gene/6653)
[UniProt: Q13487](https://www.uniprot.org/uniprot/Q13487)
[OMIM: 602214](https://www.omim.org/entry/602214)
[NCBI Gene: SORL1](https://www.ncbi.nlm.nih.gov/gene/6653)
[UniProt: Q13487](https://www.uniprot.org/uniprot/Q13487)
[OMIM: 602214](https://www.omim.org/entry/602214)
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Therapeutic Implications

Targeting the SORL1-Retromer Pathway

Given the central role of SORL1 in endosomal trafficking, several therapeutic strategies are being explored:

Retromer enhancers: Small molecules that stabilize the retromer complex can enhance SORL1-mediated APP sorting. The retromer is essential for SORL1's function — without retromer, SORL1 cannot direct APP back to the trans-Golgi network. Retromer-enhancing compounds are in development for AD and PD.

SORL1 expression modulators: Approaches to increase SORL1 expression include:

Histone deacetylase (HDAC) inhibitors that upregulate SORL1 transcription
CRISPR-based approaches to enhance SORL1 expression
TFEB (transcription factor EB) agonists that enhance lysosomal and trafficking pathways

Protein-protein interaction stabilizers: The Y1816C mutation disrupts SORL1 dimerization, which is required for retromer engagement. Developing small molecules that stabilize SORL1 dimerization could rescue function in carriers of this variant.

Endosomal Function Restoration

SORL1 deficiency causes endosomal dysfunction at multiple levels:

Endosomal trafficking enhancement: Modulators that improve endosomal transport could compensate for reduced SORL1 function

Endosomal pH normalization: BACE1 activity is pH-dependent; normalizing endosomal pH could reduce amyloidogenic processing

Lysosomal function enhancement: Improving lysosomal degradation of Aβ could compensate for reduced SORL1-mediated clearance

Gene Therapy Approaches

SORL1 is an attractive target for gene therapy:

AAV vectors can deliver functional SORL1 to neurons
In utero delivery in mouse models successfully prevents amyloid pathology
Challenges include achieving sufficient expression and avoiding overexpression artifacts

SORL1 in Parkinson's Disease

While primarily studied in AD, SORL1 variants have been implicated in Parkinson's disease:

SORL1 variants associated with PD risk in some GWAS studies
The retromer pathway is also relevant to α-synuclein trafficking
VPS35 mutations cause familial PD, linking retromer dysfunction to synucleinopathies

SORL1 in Other Neurodegenerative Conditions

ALS/FTD

SORL1 has been implicated in amyotrophic lateral sclerosis (ALS):

SORL1 variants in ALS gene panels
Endosomal dysfunction common to ALS/FTD spectrum
Interaction with TDP-43 pathology

Down Syndrome

SORL1 may play a role in Alzheimer's disease in Down syndrome:

Triplication of chromosome 21 includes APP
Endosomal dysfunction is pronounced in DS
SORL1 expression changes in DS brain

Biomarkers and Diagnostics

Soluble SORL1 as a Biomarker

Soluble SORL1 (sSORLA) in CSF and plasma:

Decreased sSORLA correlates with AD pathology
May serve as a progression marker
Can be measured by ELISA and SIMOA platforms

Genetic Testing

SORL1 genetic testing is becoming available:

Panel testing for early-onset AD
Interpretation of variants requires functional validation
Cascade testing for family members of variant carriers

Imaging Markers

SORL1 status may influence imaging biomarkers:

Endosomal enlargement on PET
CSF Aβ42 levels reflect SORL1 function
FDG-PET patterns in SORL1 carriers

Future Research Directions

Outstanding Questions

What is the full spectrum of SORL1 variants causing AD?

Can SORL1 expression be safely enhanced pharmacologically?

What determines the age of onset in SORL1 carriers?

Does SORL1 have normal functions beyond APP sorting?

Emerging Approaches

Single-cell RNA-seq to understand cell-type specific effects
Proteomics to identify SORL1 interaction networks
Human brain organoids for disease modeling
Structure-based drug design for SORL1 modulators

SORL1 Structure-Function Relationships

VPS10P Domain Architecture

The VPS10P domain is the defining feature of the SORL1 protein family:

Size: ~700 amino acids forming a 10-bladed β-propeller
Ligand binding: Binds Aβ with nanomolar affinity through a specific binding pocket
Dimerization interface: The VPS10P domains of two SORLA molecules interact to form functional dimers
Pathogenic mutations: The Y1816C mutation disrupts a conserved cysteine in this domain, impairing dimerization

The VPS10P domain shares structural homology with other VPS10P family members (sortilin, neurotensin receptor 3), but SORLA has unique ligand specificity due to specific loop insertions.

CR Domain Array

The complement-type repeat (CR) domains mediate APP binding:

Eleven CR domains arranged in tandem
APP binding site: CR domains 8-11 directly bind the Aβ region of APP
Cooperative binding: Multiple CR domains contribute to high-affinity APP interaction
pH dependence: Binding is stronger at neutral pH (TGN) and weaker at acidic pH (endosomes), facilitating ligand release

Cytoplasmic Tail Sorting Motifs

The intracellular domain contains critical sorting signals:

NPXY motifs: Two NPXY sequences that bind clathrin adaptors (Dab2, ARH)
LLL motif: A dileucine-based motif for GGAs and AP-1 recruitment
Phosphorylation sites: Serine and threonine residues that regulate adaptor binding
Retromer interaction: The cytoplasmic tail directly interacts with VPS35 of the retromer complex

Dimerization and Oligomerization

SORLA functions as a dimer:

Constitutive dimerization: SORLA forms dimers through both VPS10P and 3Fn domains
Endosomal localization: Dimerization occurs in retromer-positive endosomal tubules
Pathogenic disruption: The Y1816C mutation prevents proper dimerization
Functional consequences: Dimers are required for efficient APP sorting and retromer engagement

SORL1 in Cellular Homeostasis

Neuronal Trafficking Functions

Beyond APP, SORL1 regulates trafficking of other neuronal proteins:

Trophic factor receptors: Modulates BDNF and NGF receptor trafficking
Lipid receptors: Influences apoE receptor recycling
Ion channels: Affects neuronal excitability through trafficking regulation

Interaction with Other AD Risk Genes

SORL1 sits at a hub connecting multiple AD genetic risk factors:

BIN1: Another endosomal trafficking protein; functionally related to SORL1
PICALM: Clathrin adaptor involved in endocytosis; interacts with SORL1 pathway
CD2AP: Scaffolding protein in endosomal compartments
APOE4: Impairs endosomal function synergistically with SORL1 deficiency

This network suggests a common endosomal pathway underlying multiple genetic risk factors.

Clinical Perspectives

Genetic Counseling for SORL1 Carriers

Testing for SORL1 variants has clinical implications:

Autosomal dominant inheritance: Some variants cause AD in an autosomal dominant pattern
Incomplete penetrance: Age of onset varies among carriers
Family testing: First-degree relatives may benefit from counseling
Insurance considerations: Genetic testing may affect insurance coverage

Therapeutic Monitoring

Patients with SORL1 variants may benefit from:

Early biomarker assessment: CSF Aβ42, p-tau, and sSORLA measurements
Neuroimaging: MRI and PET to monitor disease progression
Treatment planning: May respond to anti-amyloid therapies given clear Aβ mechanism

Research Participation

Patients with SORL1 variants are valuable for research:

Natural history studies
Clinical trials targeting the amyloid pathway
Studies of retromer-enhancing compounds
iPSC and organoid modeling

References

[Rogaeva et al., The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer's Disease (2007)](https://doi.org/10.1038/ng1943)

[Andersen et al., SORL1 in Alzheimer's Disease (2005)](https://doi.org/10.1073/pnas.0503689102)

[Willnow & Andersen, Sorting receptor SORLA — a trafficking path to avoid Alzheimer's Disease (2013)](https://doi.org/10.1016/j.nbd.2013.07.011)

[Scherzer et al., SORL1 is genetically associated with late-onset AD (2004)](https://doi.org/10.1001/archneur.61.8.1200)

[Holstege et al., A familial missense variant in SORL1 impairs its maturation (2024)](https://doi.org/10.1007/s00401-023-02670-1)

[Bhalla et al., The SORL1 p.Y1816C variant causes impaired endosomal dimerization (2024)](https://doi.org/10.1073/pnas.2408262121)

[Bhalla et al., Dimerization of SORLA regulates its association with retromer (2023)](https://doi.org/10.1073/pnas.2212180120)

[Knupp et al., SORL1 is a regulator of endosomal traffic in human neurons (2022)](https://doi.org/10.1007/s00018-022-04182-9)

Additional evidence sources: [@brainspana]

Pathway Diagram

The following diagram shows the key molecular relationships involving SORL1 Protein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

SORL1 Protein

SORL1 (sortilin-Related Receptor 1)

Pathway Diagram

SORL1 (sortilin-Related Receptor 1)

Pathway Diagram

Introduction

Overview

Gene and Protein Structure

Gene

Protein Domains

Function in APP Trafficking

Normal SORL1 Function

Consequences of SORL1 Deficiency

Genetic Association with Alzheimer's Disease

GWAS and Common Variants

SORL1 as the Fourth Causal AD Gene

Role in Endosomal Pathway Dysfunction

The Endosomal Hypothesis of AD

Interaction with Retromer Complex

SORL1 Expression in the Brain

Neuronal Functions

Microglial Functions

Biomarker Potential

Relationship to Other AD Genes

Current Research Directions

Background

Brain Atlas Resources

External Links

See Also

Therapeutic Implications

Targeting the SORL1-Retromer Pathway

Endosomal Function Restoration

Gene Therapy Approaches

SORL1 in Parkinson's Disease

SORL1 in Other Neurodegenerative Conditions

ALS/FTD

Down Syndrome

Biomarkers and Diagnostics

Soluble SORL1 as a Biomarker

Genetic Testing

Imaging Markers

Future Research Directions

Outstanding Questions

Emerging Approaches

See Also

SORL1 Structure-Function Relationships

VPS10P Domain Architecture

CR Domain Array

Cytoplasmic Tail Sorting Motifs

Dimerization and Oligomerization

SORL1 in Cellular Homeostasis

Neuronal Trafficking Functions

Interaction with Other AD Risk Genes

Clinical Perspectives

Genetic Counseling for SORL1 Carriers

Therapeutic Monitoring

Research Participation

References

Pathway Diagram